David Driscoll Coloplast A/S CLPBY-OTC BUY Mar 25, 2025

(A Top Pick August 21/17, Up 24%) Colostomy bags and catheters, playing the aging demographic. Gained market share in US. Free cash flow is above competitors. Dividend grows about 10-15% per year. Investors go here to hide, so it goes up when markets go down. Buy on a pullback.

It is a Danish company which is a global leader in ostomy care and continence care, and third largest in wound care. It has done two big acquisitions. It has had some weakness in 2023 but should grow through good M&A and good R&D. It has had an 11% dividend growth rate per year and 12% share growth rate per year.       Buy 9  Hold 15  Sell 3

Prices fell hard in 2022, but has partially come back as underlying growth has been robust at 8-9% organic growth in revenue per year. It pays a 2.3% dividend and offers high growth. Are the leaders in their space.

Everyone is on the AI-hype train. But you still have the long-term demographic of aging populations. Likes the ROIC at 14% compared to WACC at 7%. Has cashflow to make tuck-in acquisitions. You get organic revenue growth plus revenue growth from the acquisitions, and this will grow the business over time and compound. The 8th wonder of the world is time plus compounding.

Medical device industry has been slow since Covid, as everything shut down and surgeries cancelled. With rising rates, customers de-stocked inventory rather than buying more. Demand starting to pick up, so they can raise prices. Exceptionally cheap for a company that can grow 15% a year.

A challenging year, partly due to slowdown in China. Many products are used after elective surgeries; overhang from Covid has slowed those surgeries. Long-term, the demand is there. Past 10 years, dividend's grown ~11% a year and shares have risen by ~12% a year. 

Healthcare will see a big turnaround over the next 1-3 years. He's buying now for clients.